查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028117

重症肌無力治療市場：規模、佔有率和成長率；全球產業分析；按類型、應用和地區分類；未來預測（2026-2034 年）

Myasthenia Gravis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

重症肌無力治療市場的成長要素

2025年全球重症肌無力治療市場規模為16.2億美元，預計2026年將成長至17.5億美元，到2034年將達到32.1億美元，預測期內（2026-2034年）複合年成長率為7.89%。北美地區憑藉其完善的醫療基礎設施、較高的疾病認知度和獲得先進治療方法，在2025年佔據市場主導地位，市場佔有率達49.25%。

重症肌無力（MG）是一種罕見的自體免疫疾病，其特徵是由於神經肌肉傳遞受損而導致的肌肉無力。此病患病率不斷上升，尤其是在老年族群中，這大大促進了市場擴張。

市場趨勢

影響市場格局的關鍵趨勢之一是向新型標靶治療方法的轉變。由於傳統治療方法常常引起副作用，患者和醫療專業人員擴大採用先進的生物製藥和單株抗體。

製藥公司正大力投資研發，以期將創新藥物推向市場。例如，fgultigimod 和單株抗體等治療方法因其療效和安全性的提升而備受關注。此外，皮下注射免疫球蛋白 (SCIg) 療法的出現，為居家照護提供了便利，提高了患者的醫療體驗。

市場促進因素

疾病盛行率上升

重症肌無力（MG）在全球的盛行率不斷上升，是成長要素。研究估計，全球有超過70萬名患者，光是美國就有約3.6萬至6萬例。診斷能力的提高和宣傳活動意識的增強，進一步增加了對該疾病的治療需求。

人口老化

這種疾病在老年人中更為常見，隨著全球老年人口的不斷成長，對有效治療方法的需求也日益增加。預期壽命的延長直接導致了該疾病發生率的上升。

強大的研發管線和新藥認證

Argenx、CSL Behring 和 F. Hoffmann-La Roche Ltd. 等主要企業正在積極研發先進治療方法。監管部門核准數量的不斷增加正在加速市場成長。

市場限制因素

抑制因子

儘管成長強勁，市場仍面臨諸多挑戰：

  • 治療費用高昂：與其他慢性疾病相比，治療費用可能高得多，而且獲得治療的機會有限。
  • 發展中地區保險報銷的限制：保險覆蓋不足導致自付費用增加。
  • 醫療基礎設施差距：新興國家在獲得診斷和治療方面仍面臨挑戰。

這些因素可能會阻礙市場擴張，尤其是在中低收入國家。

基於細分市場的分析

藥物類別

市場依藥物類別細分為膽鹼酯酶抑制劑、皮質類固醇、免疫抑制劑、靜脈注射免疫球蛋白及其他藥物。

  • 由於靜脈注射免疫球蛋白 (IVIg) 在長期治療中療效顯著且副作用較少，預計到 2026 年，IVIg 將佔據市場主導地位，市場佔有率達到 77.18%。
  • 由於對標靶治療的需求不斷成長，單株抗體領域預計將顯著成長。

透過分銷管道

  • 受住院率上升和醫生監管要求增加的推動，預計醫院藥房將佔據最大的市場佔有率（到 2026 年將達到 45.36%）。
  • 由於數位化技術的進步和便利性的提高，預計網路藥局將呈現最快的成長速度。

區域展望

北美洲

預計北美將在 2025 年以 8 億美元市場規模引領市場，並在 2026 年成長至 8.6 億美元。這一成長是由高疾病盛行率、先進的醫療保健系統和有利的報銷政策所推動的。

歐洲

預計到 2025 年，歐洲的罕見疾病研究經費將達到 4.5 億美元，到 2026 年將達到 4.8 億美元。資金投入的增加和人們對罕見疾病研究認知的提高是成長要素。

亞太地區

預計該地區2025年市場規模將達2.3億美元，2026年將達2.5億美元。由於醫療基礎設施的改善和診斷率的提高，預計該地區將以最高的複合年成長率成長。

其他地區（ROW）

在拉丁美洲和中東等地區，由於人們健康意識的提高和醫療保健服務覆蓋範圍的擴大，醫療保健產業正逐步發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章 主要考慮因素

  • 產業重大發展動態（企業合併、商業合作）
  • 新產品發布：按主要企業分類
  • 新冠疫情對市場的影響

第5章：全球重症肌無力治療市場分析：探討與預測（2021-2034年）

  • 市場分析、洞察與預測：按藥物類別分類
    • 膽鹼酯酶抑制劑
    • 皮質類固醇
    • 免疫抑制劑
    • IVIg
    • 單株抗體
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 網路藥房
    • 零售藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美重症肌無力治療市場分析：探討與預測（2021-2034 年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲重症肌無力治療市場分析：探討與預測（2021-2034 年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區重症肌無力治療市場分析：探討與預測（2021-2034）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 其他亞太國家

第9章：其他地區（ROW）重症肌無力治療市場分析：探討與預測（2021-2034 年）

第10章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • AstraZeneca
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Veloxis Pharmaceuticals, Inc.
    • Bausch Health Companies Inc.
Product Code: FBI106405

Growth Factors of myasthenia gravis treatment Market

The global myasthenia gravis treatment market was valued at USD 1.62 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, reaching USD 3.21 billion by 2034, exhibiting a CAGR of 7.89% during the forecast period (2026-2034). North America dominated the market with a 49.25% share in 2025, driven by strong healthcare infrastructure, high disease awareness, and access to advanced therapies.

Myasthenia gravis (MG) is a rare autoimmune disorder characterized by muscle weakness caused by disrupted nerve-muscle communication. Increasing prevalence, especially among the aging population, is significantly contributing to market expansion.

Market Trends

A key trend shaping the market is the growing shift toward novel and targeted therapies. Conventional treatments often cause side effects, encouraging patients and healthcare providers to adopt advanced biologics and monoclonal antibodies.

Pharmaceutical companies are investing heavily in R&D to introduce innovative drugs. For instance, therapies such as efgartigimod and monoclonal antibodies are gaining traction due to improved efficacy and safety profiles. Additionally, subcutaneous immunoglobulin (SCIg) therapies are emerging, supporting home-based care and improving patient convenience.

Market Growth Factors

Rising Disease Prevalence

The increasing global prevalence of MG is a major growth driver. Studies estimate over 700,000 patients worldwide, with 36,000-60,000 cases in the U.S. alone. Improved diagnostic capabilities and awareness campaigns are further boosting treatment demand.

Aging Population

The condition is more common among older adults, and with the global geriatric population rising, the demand for effective treatments is increasing. Higher life expectancy is directly contributing to higher disease incidence rates.

Strong Pipeline and Drug Approvals

Leading companies such as Argenx, CSL Behring, and F. Hoffmann-La Roche Ltd. are actively developing advanced therapies. Increasing approvals from regulatory authorities are accelerating market growth.

Restraining Factors

Despite positive growth, the market faces certain challenges:

  • High Treatment Costs: Treatment expenses can be significantly higher compared to other chronic diseases, limiting accessibility.
  • Limited Reimbursement in Developing Regions: Inadequate insurance coverage increases out-of-pocket expenses.
  • Healthcare Infrastructure Gaps: Emerging economies still face challenges in diagnosis and treatment access.

These factors may hinder market expansion, particularly in low- and middle-income countries.

Segmentation Analysis

By Drug Class

The market is segmented into cholinesterase inhibitors, corticosteroids, immunosuppressants, IVIg, and others.

  • The IVIg segment dominated with a 77.18% share in 2026, owing to its effectiveness in long-term treatment and fewer side effects.
  • The monoclonal antibodies segment is expected to witness significant growth due to increasing demand for targeted therapies.

By Distribution Channel

  • Hospital pharmacies held the largest share (45.36% in 2026), driven by higher hospitalization rates and physician supervision requirements.
  • Online pharmacies are projected to grow at the fastest rate due to increasing digital adoption and convenience.

Regional Insights

North America

North America led the market with USD 0.8 billion in 2025, growing to USD 0.86 billion in 2026. Growth is supported by high disease prevalence, advanced healthcare systems, and favorable reimbursement policies.

Europe

Europe accounted for USD 0.45 billion in 2025 and is projected to reach USD 0.48 billion in 2026. Increasing funding for rare disease research and rising awareness are key growth drivers.

Asia Pacific

The region generated USD 0.23 billion in 2025 and is expected to reach USD 0.25 billion in 2026. It is projected to grow at the highest CAGR due to improving healthcare infrastructure and rising diagnosis rates.

Rest of the World

Regions such as Latin America and the Middle East are witnessing gradual growth due to increasing awareness and expanding healthcare access.

Key Industry Players

Major companies operating in the market include:

  • AstraZeneca
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bausch Health Companies Inc.

These players focus on strategic collaborations, acquisitions, and product innovation to strengthen their market position.

Key Industry Developments

  • 2023: UCB S.A. received FDA approval for ZILBRYSQ for generalized MG.
  • 2023: AstraZeneca's Soliris approved in Japan for pediatric MG treatment.
  • 2021: Argenx filed for FDA approval of efgartigimod.
  • Ongoing partnerships and clinical trials are accelerating innovation in the market.

Conclusion

The global myasthenia gravis treatment market is poised for steady growth from USD 1.62 billion in 2025 to USD 3.21 billion by 2034, driven by rising disease prevalence, increasing awareness, and advancements in novel therapies. While high treatment costs and limited reimbursement remain key challenges, continuous R&D investments and the introduction of targeted biologics are expected to transform the treatment landscape. Overall, the market presents strong growth opportunities, particularly with the shift toward personalized medicine and improved healthcare access worldwide.

Segmentation By Drug Class

  • Cholinesterase Inhibitors
  • Corticosteroids
  • Immunosuppressants
  • IVIg
  • Monoclonal Antibodies

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug Class, By Distribution Channel, and By Country)
    • U.S. (By Drug Class)
    • Canada (By Drug Class)
  • Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
    • U.K. (By Drug Class)
    • Germany (By Drug Class)
    • France (By Drug Class)
    • Italy (By Drug Class)
    • Spain (By Drug Class)
    • Scandinavia (By Drug Class)
    • Rest of Europe (By Drug Class)
  • Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
    • Japan (By Drug Class)
    • India (By Drug Class)
    • China (By Drug Class)
    • Australia (By Drug Class)
    • Rest of Asia Pacific (By Drug Class)
  • Rest of the World (By Drug Class, By Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Key Industry Developments (Mergers, Acquisitions, and Partnership)
  • 4.2. New Product Launches, by Key Players
  • 4.3. Impact of COVID-19 on the Market

5. Global Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Cholinesterase Inhibitors
    • 5.1.2. Corticosteroids
    • 5.1.3. Immunosuppressants
    • 5.1.4. IVIg
    • 5.1.5. Monoclonal Antibodies
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Online Pharmacies
    • 5.2.3. Retail Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Geography
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of World

6. North America Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Cholinesterase Inhibitors
    • 6.1.2. Corticosteroids
    • 6.1.3. Immunosuppressants
    • 6.1.4. IVIg
    • 6.1.5. Monoclonal Antibodies
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Online Pharmacies
    • 6.2.3. Retail Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
      • 6.3.1.1. By Drug Class
    • 6.3.2. Canada
      • 6.3.2.1. By Drug Class

7. Europe Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Cholinesterase Inhibitors
    • 7.1.2. Corticosteroids
    • 7.1.3. Immunosuppressants
    • 7.1.4. IVIg
    • 7.1.5. Monoclonal Antibodies
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Online Pharmacies
    • 7.2.3. Retail Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.3.1. U.K.
      • 7.3.1.1. By Drug Class
    • 7.3.2. Germany
      • 7.3.2.1. By Drug Class
    • 7.3.3. France
      • 7.3.3.1. By Drug Class
    • 7.3.4. Spain
      • 7.3.4.1. By Drug Class
    • 7.3.5. Italy
      • 7.3.5.1. By Drug Class
    • 7.3.6. Scandinavia
      • 7.3.6.1. By Drug Class
    • 7.3.7. Rest of Europe
      • 7.3.7.1. By Drug Class

8. Asia Pacific Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Cholinesterase Inhibitors
    • 8.1.2. Corticosteroids
    • 8.1.3. Immunosuppressants
    • 8.1.4. IVIg
    • 8.1.5. Monoclonal Antibodies
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Online Pharmacies
    • 8.2.3. Retail Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.3.1. Japan
      • 8.3.1.1. By Drug Class
    • 8.3.2. China
      • 8.3.2.1. By Drug Class
    • 8.3.3. India
      • 8.3.3.1. By Drug Class
    • 8.3.4. Australia
      • 8.3.4.1. By Drug Class
    • 8.3.5. Rest of Asia Pacific
      • 8.3.5.1. By Drug Class

9. Rest of World Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Cholinesterase Inhibitors
    • 9.1.2. Corticosteroids
    • 9.1.3. Immunosuppressants
    • 9.1.4. IVIg
    • 9.1.5. Monoclonal Antibodies
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Online Pharmacies
    • 9.2.3. Retail Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. AstraZeneca
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & Services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Astellas Pharma Inc.
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & Services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. F. Hoffmann-La Roche Ltd.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & Services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Novartis AG
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & Services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Veloxis Pharmaceuticals, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & Services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Bausch Health Companies Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & Services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 3: Global Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 4: North America Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 5: North America Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: North America Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: U.S. Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: Canada Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 9: Europe Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 11: Europe Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 12: Germany Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 13: U.K. Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: France Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 15: Italy Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: Spain Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Scandinavia Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Rest of Europe Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 19: Asia Pacific Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Asia Pacific Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Japan Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: India Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 24: China Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 25: Australia Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Rest of Asia Pacific Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Rest of World Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 28: Rest of World Myasthenia Gravis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Myasthenia Gravis Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Myasthenia Gravis Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Myasthenia Gravis Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 4: Global Myasthenia Gravis Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 5: North America Myasthenia Gravis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 6: North America Myasthenia Gravis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 7: North America Myasthenia Gravis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 8: North America Myasthenia Gravis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 9: North America Myasthenia Gravis Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Myasthenia Gravis Treatment Market Value Share (%), By Country, 2025
  • Figure 11: Europe Myasthenia Gravis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 12: Europe Myasthenia Gravis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 13: Europe Myasthenia Gravis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: Europe Myasthenia Gravis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: Europe Myasthenia Gravis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Myasthenia Gravis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Myasthenia Gravis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Asia Pacific Myasthenia Gravis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 19: Asia Pacific Myasthenia Gravis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: Asia Pacific Myasthenia Gravis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: Asia Pacific Myasthenia Gravis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Myasthenia Gravis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Rest of World Myasthenia Gravis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 24: Rest of World Myasthenia Gravis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 25: Rest of World Myasthenia Gravis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 26: Rest of World Myasthenia Gravis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 27: Global Myasthenia Gravis Treatment Market Share (%), By Company, 2025